The New-Generation Selective ROS1/NTRK Inhibitor DS-6051b Overcomes Crizotinib Resistant ROS1-G2032R Mutation in Preclinical Models

Nature Communications - United Kingdom
doi 10.1038/s41467-019-11496-z